{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:16:41Z","timestamp":1792444601611,"version":"4.5.0"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["Researcher Supporting Project (RSP\u20102021\/77)"],"award-info":[{"award-number":["Researcher Supporting Project (RSP\u20102021\/77)"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP\u20102021\/77"],"award-info":[{"award-number":["RSP\u20102021\/77"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity Reviews"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Tirzepatide is a new glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101RA) that has shown promising results for weight loss. A Bayesian network meta\u2010analysis was conducted to compare the efficacy and safety of GLP\u20101RAs for obesity management. Embase and MEDLINE were searched looking for randomized clinical trials (RCTs) that evaluated the efficacy of GLP\u20101RAs for weight loss in patients without diabetes. The main efficacy outcomes evaluated were the mean change in actual and percentage weight loss and the proportion of patients with weight loss of \u22655%\u201320%. Main safety outcomes evaluated include nausea, vomiting, diarrhea, constipation, loss of appetite, pancreatitis, gallbladder\u2010related disorders, and withdrawal due to adverse events. Seven RCTs with more than 12,300 patients were analyzed, including patients with body mass index (BMI)\u2009\u2265\u200930\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , or BMI\u2009\u2265\u200927\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    with comorbidities. Weekly tirzepatide 10 and 15\u2009mg resulted in more weight loss than weekly semaglutide 2.4\u00a0mg, daily semaglutide 0.4\u00a0mg, or liraglutide 3\u00a0mg. Tirzepatide and weekly semaglutide demonstrated comparable results but with significantly higher odds of achieving \u22655%\u201320% weight loss compared with liraglutide. GLP\u20101RAs triggered more gastrointestinal adverse events than placebo, with no in\u2010between difference. Although all GLP\u20101RAs lead to significant weight reduction, tirzepatide was associated with better efficacy outcomes while having a comparable safety profile.\n                  <\/jats:p>","DOI":"10.1111\/obr.13543","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T06:15:58Z","timestamp":1672294558000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Comparative effectiveness of glucagon\u2010like peptide\u20101 receptor agonists for the management of obesity in adults without diabetes: A network meta\u2010analysis of randomized clinical trials"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7714-2945","authenticated-orcid":false,"given":"Omar S.","family":"Alkhezi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Department of Pharmacy Practice, Unaizah College of Pharmacy Qassim University  Qassim Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-5535","authenticated-orcid":false,"given":"Abdullah A.","family":"Alahmed","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Department of Pharmacy Practice, College of Pharmacy Qassim University  Qassim Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-6508","authenticated-orcid":false,"given":"Osamah M.","family":"Alfayez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy Qassim University  Qassim Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama A.","family":"Alzuman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-0606","authenticated-orcid":false,"given":"Abdulaali R.","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Drug Sector Saudi Food and Drug Authority  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-4106","authenticated-orcid":false,"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy King Saud University  Riyadh Saudi Arabia"},{"name":"Pharmacoeconomics Research Unit, College of Pharmacy King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"World Health Organization.Obesity and overweight.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Published 2021. Updated 9 June 2021. Accessed 4 July 2022."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u20109\u201088"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)30175\u20101"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10432"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds017\u20100025"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613489721"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.8714"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010020\u201001070\u2010z"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01640\u20108"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13435"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010021\u201002945\u20101"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10050985"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.008"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154\u2010014\u20109289\u20105"},{"key":"e_1_2_8_17_1","unstructured":"U.S. Food and Drug Administration.Saxenda injection.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206321Orig1s000TOC.cfm. Published 2014. Accessed 4 July 2022."},{"key":"e_1_2_8_18_1","unstructured":"U.S. Food and Drug Administration.FDA approves new drug treatment for chronic weight management.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Published 2021. Accessed 4 July 2022."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006"},{"key":"e_1_2_8_20_1","unstructured":"U.S. Food and Drug Administration.FDA approves novel dual\u2010targeted treatment for type 2 diabetes.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-dual-targeted-treatment-type-2-diabetes. Updated 13 May 2022. Accessed 4 July 2022."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1373"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2016.10.003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)30069\u20107"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)31773\u20102"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101213"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE\u201019\u20100566"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.2002616"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010022\u201005715\u20104"},{"key":"e_1_2_8_35_1","unstructured":"ZolerML.Tirzepatide's retail price set at about $12 666 per year. Medscape Medical News website.https:\/\/www.medscape.com\/viewarticle\/974390. Published2022. Accessed 4 July 2022."},{"key":"e_1_2_8_36_1","unstructured":"LinGA BrouwerE NikitinD MoradiA ChenY Herron\u2010SmithS HansenRN PearsonSD CampbellJD.Tirzepatide for type 2 diabetes; evidence report. Institute for Clinical and Economic Review.https:\/\/icer.org\/assessment\/diabetes-type-2-2022\/#timeline. Published2022. Updated 6 January 2022. Accessed 4 July 2022."},{"key":"e_1_2_8_37_1","unstructured":"Novo Nordisk. Victoza\u00ae.https:\/\/www.novopricing.com\/victoza.html. Accessed 4 July 2022."},{"key":"e_1_2_8_38_1","unstructured":"Novo Nordisk. Saxenda\u00ae.https:\/\/www.novopricing.com\/saxenda.html. Accessed 4 July 2022."},{"key":"e_1_2_8_39_1","unstructured":"Novo Nordisk. Ozempic\u00ae.https:\/\/www.novopricing.com\/ozempic.html. Accessed 4 July 2022."},{"key":"e_1_2_8_40_1","unstructured":"Novo Nordisk. Wegovy\u00ae.https:\/\/www.novopricing.com\/wegovy.html. Accessed 4 July 2022."}],"container-title":["Obesity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/obr.13543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/obr.13543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/obr.13543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T04:47:50Z","timestamp":1692506870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/obr.13543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/obr.13543"],"URL":"https:\/\/doi.org\/10.1111\/obr.13543","archive":["Portico"],"relation":{},"ISSN":["1467-7881","1467-789X"],"issn-type":[{"value":"1467-7881","type":"print"},{"value":"1467-789X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"2022-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13543"}}